secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adagio Medical Holdings, Inc. (ADGM)
CIK:        0002006986
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0001104659-25-018724
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adagio Medical restructures to focus on US pivotal IDE trial; reduces workforce
-------------------------------------------------------------------------------

- Pauses limited European launch of vCLAS catheter; redirects resources to US FULCRUM-VT Pivotal IDE trial (over 35% enrolled).
- Reduction in force effective February 28, 2025, to enable additional investment in clinical trial and product design optimization.
- Streamlining operations and realigning resources toward US FDA premarket approval for VT Cryoablation System with vCLAS catheter.
- CEO Todd Usen cites broad applicability of ultra-low temperature cryoablation technology and aim to lead ventricular tachycardia market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2006986/000110465925018724/0001104659-25-018724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2006986/000110465925018724/tm257750d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-018724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer